Innoviva, Inc. Common Stock vs. Johnson & Johnson
Innoviva, Inc. Common Stock (INVA) comes out ahead, leading on 7 of 11 compared factors.
Size & Scale
| INVA | JNJ | |
|---|---|---|
| Market Cap | $1.50 billion | $653.61 billion |
| Revenue (TTM) | $440.00 million | $97.93 billion |
| Net Income (TTM) | $357.24 million | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| INVA | JNJ | |
|---|---|---|
| P/E Ratio | 5.19 | 31.59 |
| Price / Book | 1.21 | 7.69 |
| Price / Sales | 3.41 | 6.67 |
INVA leads on 3 of 3 valuation factors.
Profitability
| INVA | JNJ | |
|---|---|---|
| Net Margin | 81.19% | 21.48% |
| Return on Equity | 28.97% | 24.76% |
INVA leads on 2 of 2 profitability factors.
Dividend
| INVA | JNJ | |
|---|---|---|
| Dividend Yield | 4.69% | 1.97% |
| Payout Ratio | 24.33 | 62.18 |
INVA leads on 2 of 2 dividend factors.
Risk & Sentiment
| INVA | JNJ | |
|---|---|---|
| Short Interest | 19.43% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: INVA overview, INVA financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
